Loading asset research
Palvella Therapeutics Inc. Common Stock
PVLANasdaq · USD · StocksQuote as of · Exchange session not verified$150.13
-0.17%
Today
PVLA
Loading 1D prices…
Market cap
$2.2B
Volume
163.3K
52w high
$161.3852w low
$53.30Company profile
Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Wayne, PA, United States
Employees
29
Fiscal year end
1231
CIK
1583648
Session & valuation
Open$152.75
Previous close$150.39
Day high$154.30
Day low$149.98
30-day avg. volume186K
Outstanding shares14.4M
Diluted EPS-$3.71
Latest annual period
P/E (trailing)-40.47
P/E (forward)-20.02
Price / book9.97
Beta—
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| SRPTSarepta Therapeutics Inc. Common Stock (DE) | $2.2B | $1.9B | -38.27% | -$7.13 | -0.29% | Hold |
| AUPHAurinia Pharmaceuticals Inc Ordinary Shares | $2.1B | $283.1M | +101.46% | $2.07 | -0.09% | Buy |
| BHCBausch Health Companies Inc. Common Stock | $2.2B | $10.3B | +1.53% | $0.42 | -3.46% | Hold |
| NUVBNuvation Bio Inc. Class A Common Stock | $2.1B | $62.9M | -325.31% | -$0.60 | -3.42% | Buy |
| PBHPrestige Consumer Healthcare Inc. Common Stock | $2.2B | $1.1B | +17.48% | $3.91 | -0.82% | Hold |